Olmesartan Medoxomilo Tolife

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomilo Tolife, is an Angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It treats hypertension in adult patients by lowering elevated blood pressure. GNH USA supplies Olmesartan Medoxomilo Tolife as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil is an ARB that addresses conditions related to the renin‑angiotensin system, primarily hypertension. - Hypertension: lowers elevated systolic and diastolic blood pressure in patients with high blood pressure. - Essential hypertension: provides long‑term blood pressure control to reduce cardiovascular risk. - High blood pressure: improves overall cardiovascular health by decreasing vascular resistance.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or tiredness. - Nasal congestion. - Diarrhea. - Cough.

Serious or Rare Side Effects: - Hyperkalemia (elevated blood potassium levels). - Acute kidney injury or worsening renal function. - Angioedema (swelling of face, lips, tongue, or throat). - Severe hypotension. - Liver enzyme abnormalities. - Allergic skin reactions such as rash or urticaria.

Before initiating therapy, consider the following precautions: - Renal impairment: assess kidney function and monitor serum creatinine. - Hepatic disease: use with caution in patients with liver dysfunction. - Electrolyte disturbances: monitor potassium levels, especially if combined with potassium‑sparing agents. - Concomitant antihypertensives: watch for additive blood‑pressure lowering effects. - Pregnancy: avoid use; discuss alternative therapies with a healthcare professional. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Olmesartan medoxomil may interact with several drug classes. Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment: increased risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and impair renal function. Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, beta‑blockers): may enhance blood‑pressure lowering. - Lithium: increased lithium levels, monitor for toxicity. - Diuretics (thiazides): may increase risk of electrolyte imbalance.